OBJECTIVE: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. METHODS: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. RESULTS: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. CONCLUSIONS: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.
OBJECTIVE: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. METHODS: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. RESULTS: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. CONCLUSIONS: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.
Authors: O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón Journal: J Neurol Date: 2010-04-10 Impact factor: 4.849
Authors: Graziella Filippini; Lorenzo Moja; Alessandro Liberati; Gian Franco Gensini; Roberto Gusinu; Andrea A Conti Journal: Intern Emerg Med Date: 2008-09 Impact factor: 3.397
Authors: F Patti; T Cavallaro; S Lo Fermo; A Nicoletti; V Cimino; R Vecchio; P Laisa; R Zarbo; M Zappia Journal: J Neurol Date: 2008-07-28 Impact factor: 4.849
Authors: A Rovira Cañellas; A Rovira Gols; J Río Izquierdo; M Tintoré Subirana; X Montalban Gairin Journal: Neuroradiology Date: 2007-02-28 Impact factor: 2.995